CAPELLA – Sponsored by Regeneron Pharmaceuticals, Inc.Completed Study | Duration: 52 weeks
CAPELLA was a multi-center, prospective, and randomized Phase II clinical trial for the treatment of wet Age-Related Macular Degeneration (wet AMD). It compared the efficacy of intravitreal REGN2176-3 vs. intravitreal Eylea mono therapy. REGN2176-3 is a new drug that is a combination of Eylea (anti-VEGF) plus an anti-PDGFRβ. PDGF plays a major role in the blood vessel stability, and blockade of PDGFRβ prevents the effects of several subclasses of PDGF. This mechanism in conjunction with anti-VEGF therapy should improve treatment for wet AMD. This trial was for patients with newly diagnosed wet AMD who have received no prior anti- VEGF treatment. Participants were treated and followed for 52 weeks, and primary outcome was measured at the 12-weeks mark.